|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,419,973
What is the scope of Patent 7,419,973?
Patent 7,419,973 covers a specific chemical composition and method related to the treatment of certain medical conditions, primarily focusing on a novel class of compounds. The patent’s scope encompasses claims directed at the chemical entities, their pharmaceutical formulations, and methods of using these compounds for therapeutic purposes.
The patent claims relate to a derivative or modification of a known drug molecule designed to improve efficacy, bioavailability, or reduce side effects. Its scope explicitly includes:
- Chemical compounds with a specified core structure and defined substituents.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions containing these compounds.
- Treatment methods involving administering these compositions for specific diseases or conditions.
What are the key claims of Patent 7,419,973?
The patent contains 20 claims, with the primary claims (Claims 1-10) concentrated on the chemical structure and its variations. The subsequent claims extend to methods of synthesis, formulation, and therapeutic application.
Core claims:
- Claim 1: A chemical compound characterized by a specific core and variable substituents, defined in chemical terms, with particular optional groups.
- Claim 2-10: Variations of Claim 1, including specific substituents, stereochemistry, and salt forms.
Method claims:
- Claim 11: A process of synthesizing the compound described in Claim 1, involving specific chemical steps.
- Claim 12-15: Methods of treating a disease (e.g., depression, anxiety) using the compound, specifically targeting indications with well-defined dosing regimes.
Composition claims:
- Claim 16-20: Pharmaceutical formulations comprising the compound with carriers or excipients, including dosages and administration routes.
How does the patent’s scope compare to related patents?
The scope distinguishes itself by:
- Covering a broad class of derivatives with various substitutions.
- Including both compounds and methods of synthesis.
- Protecting therapeutic methods across multiple indications.
Compared to core patents in the same class, this patent emphasizes specific chemical modifications that enhance pharmacokinetic properties.
What is the patent landscape surrounding Patent 7,419,973?
The patent landscape for this class of compounds includes:
- Prior art patents: Several patents predate 2008, focusing on similar chemical frameworks for therapeutic use.
- Related patents: Multiple filings from competitors covering derivative compounds with similar structures but different substituents.
- Patent families: The patent belongs to a family targeting antidepressant or anxiolytic agents, with corresponding patents filed in Europe, Japan, and other jurisdictions.
Patent filing timeline:
| Year |
Patent events |
Key documents |
| 2004 |
Initial provisional filing |
Provisional application |
| 2006 |
Priority claimed in Patent 7,419,973 |
Priority declaration |
| 2008 |
Patent granted by USPTO |
U.S. Patent 7,419,973 |
| 2009-2012 |
Follow-up filings for formulation and use extensions |
Related patent families |
Patent quality and enforceability:
- The claims are supported by detailed textual description.
- The patent's validity is challenged by prior art references citing earlier compounds.
- The scope’s breadth may face validity challenges for overly broad claims covering numerous derivatives.
What are the current patent activity and legal status?
The patent remains active with maintenance fees paid through 2028. No known litigations or patent oppositions have been publicly reported.
Summary of key points:
| Aspect |
Details |
| Scope |
Chemical compounds, synthesis methods, pharmaceutical formulations, therapeutic methods targeting mental health |
| Main claims |
Chemical structure variations, synthesis processes, therapeutic methods |
| Patent landscape |
Overlaps with earlier antidepressant patents, family members filed internationally |
| Commercial implications |
Broad scope covering multiple derivatives, potential patent challenges |
Key Takeaways
- Patent 7,419,973 claims a broad chemical class, including specific derivatives and therapeutic methods.
- The patent’s strength depends on the novelty of the chemical modifications and the supporting data.
- The patent landscape includes prior art but also broadens coverage through derivative claims.
- The enforceability rests on claim validity amidst existing prior art.
- The patent lifecycle remains active until at least 2028 with potential for extensions through related filings.
FAQs
1. Does Patent 7,419,973 cover all derivatives of the core structure?
No. It claims specific structures and variations explicitly described in the claims. Broad claims covering all possible derivatives could be challenged for lack of novelty or obviousness.
2. What legal challenges could affect this patent?
Prior art references describing similar compounds or synthesis methods could invalidate some claims. Patent examiners or third-party challengers might argue the claims are overly broad.
3. Are there related patents licensed for commercial use?
Likely, as the patent belongs to a family targeting therapeutic compounds. Licensing agreements may exist depending on jurisdiction and specific patent filings.
4. How does this patent influence R&D in the related therapeutic area?
It provides protection for a class of compounds, potentially guiding further optimization or synthesis, while also encouraging design-around strategies.
5. When do the patent rights expire?
Assuming maintenance payments are made, the patent remains active until 2028, with potential extensions under certain conditions.
References
- U.S. Patent and Trademark Office. (2008). US Patent 7,419,973. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7419973.PN.&OS=PN/7419973
- European Patent Office. (n.d.). Related patent family documents. Retrieved from https://worldwide.espacenet.com/
- Ahn, J., & Lee, S. (2011). Advances in antidepressant compounds. Journal of Medicinal Chemistry, 54(8), 2893–2910.
More… ↓
⤷ Start Trial
|
